Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern

[1]  G. Biele,et al.  Estimating infectiousness throughout SARS-CoV-2 infection course , 2021, Science.

[2]  M. Shankar-Hari,et al.  Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection , 2021, The Journal of infectious diseases.

[3]  T. Teshima,et al.  A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study , 2021, The Lancet Microbe.

[4]  P. Galle,et al.  Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at hospital admission , 2021, Medical Microbiology and Immunology.

[5]  P. Galle,et al.  Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at hospital admission , 2021, Medical microbiology and immunology.

[6]  M. Van Ranst,et al.  Comparison of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-19 in Symptomatic and Asymptomatic Outpatients , 2021, Journal of clinical microbiology.

[7]  M. Singer,et al.  Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study , 2021, The Lancet Infectious Diseases.

[8]  M. Capobianchi,et al.  Lumipulse G SARS-CoV-2 Ag assay evaluation using clinical samples from different testing groups , 2021, Clinical chemistry and laboratory medicine.

[9]  M. Gilbert,et al.  SARS-CoV-2 Diagnostic Tests: Algorithm and Field Evaluation From the Near Patient Testing to the Automated Diagnostic Platform , 2021, Frontiers in Medicine.

[10]  H. Mikamo,et al.  Efficacy and validity of automated quantitative chemiluminescent enzyme immunoassay for SARS-CoV-2 antigen test from saliva specimen in the diagnosis of COVID-19 , 2021, Journal of Infection and Chemotherapy.

[11]  A. Baiker,et al.  Detection of the new SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs), Germany, March 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  G. Ippolito,et al.  Saliva Is a Valid Alternative to Nasopharyngeal Swab in Chemiluminescence-Based Assay for Detection of SARS-CoV-2 Antigen , 2021, Journal of clinical medicine.

[13]  L. Hooft,et al.  Rapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection , 2021, The Cochrane database of systematic reviews.

[14]  A. Godzik,et al.  Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[15]  Sergei L. Kosakovsky Pond,et al.  Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[16]  L. Danon,et al.  Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study , 2021, BMJ.

[17]  P. Calistri,et al.  Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs , 2021, International Journal of Infectious Diseases.

[18]  A. Mencacci,et al.  Evaluation of Lumipulse® G SARS-CoV-2 antigen assay automated test for detecting SARS-CoV-2 nucleocapsid protein (NP) in nasopharyngeal swabs for community and population screening , 2021, International Journal of Infectious Diseases.

[19]  C. Ascoli.  Could mutations of SARS-CoV-2 suppress diagnostic detection? , 2021, Nature Biotechnology.

[20]  S. Atabani,et al.  S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR , 2021, The Journal of infectious diseases.

[21]  M. Maejima,et al.  Prospective study of 1308 nasopharyngeal swabs from 1033 patients using the LUMIPULSE SARS-CoV-2 antigen test: Comparison with RT-qPCR , 2021, International Journal of Infectious Diseases.

[22]  L. Kaderali,et al.  Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting , 2021, Medical microbiology and immunology.

[23]  H. Blum,et al.  Prospective Longitudinal Serosurvey of Health Care Workers in the First Wave of the SARS-CoV-2 Pandemic in a Quaternary Care Hospital in Munich, Germany , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  J. Dogné,et al.  Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection , 2021, Journal of clinical medicine.

[25]  S. Hoehl,et al.  Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread? , 2020, Journal of Clinical Virology.

[26]  E. Möncke-Buchner,et al.  Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests , 2020, medRxiv.

[27]  P. Simmonds,et al.  Virological and serological characterization of critically ill patients with COVID-19 in the UK: Interactions of viral load, antibody status and B.1.1.7 variant infection , 2021 .

[28]  S. Yagi,et al.  Clinical validation of quantitative SARS-CoV-2 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs , 2020, Journal of Infection and Chemotherapy.

[29]  Devy M. Emperador,et al.  Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection , 2020, The Cochrane database of systematic reviews.

[30]  M. Maejima,et al.  Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients , 2020, International Journal of Infectious Diseases.

[31]  H. Blum,et al.  Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[32]  W. Organization.  Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays , 2020 .

[33]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[34]  Y. Ashihara,et al.  Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers. , 1991, Clinical chemistry.